DOI QR코드

DOI QR Code

Development of Multidrug Resistance during Standardized Treatment in a Patient with Drug-Sensitive Tuberculosis

약제 감수성 폐결핵 환자의 초 치료 중 발생한 다제내성 결핵

  • Jeong, Yun-Jeong (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) ;
  • Kang, Hyo-Jae (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) ;
  • Choi, Sun-Mi (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) ;
  • Han, Sung-Koo (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) ;
  • Yim, Jae-Joon (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine)
  • 정윤정 (서울대학교 의과대학 내과학교실, 의학연구원 폐 연구소) ;
  • 강효재 (서울대학교 의과대학 내과학교실, 의학연구원 폐 연구소) ;
  • 최선미 (서울대학교 의과대학 내과학교실, 의학연구원 폐 연구소) ;
  • 한성구 (서울대학교 의과대학 내과학교실, 의학연구원 폐 연구소) ;
  • 임재준 (서울대학교 의과대학 내과학교실, 의학연구원 폐 연구소)
  • Published : 2012.05.01

Abstract

Standard short-course chemotherapy (SSC) is recommended for new patients with pulmonary tuberculosis (TB). This approach has been regarded as among the most effective tools for preventing the development of resistance to anti-TB drugs. We report on the development of multidrug-resistance during SSC in a patient with drug-susceptible TB. Isoniazid, rifampin, pyrazinamide, and ethambutol were started, and negative culture conversion was obtained. Ethambutol was discontinued after 5 weeks of treatment due to visual dysfunction, and pyrazinamide was discontinued after a 2-month phase of intensive treatment. However, M. tuberculosis was cultivated from sputum collected after 9 weeks of treatment. Drug-susceptibility testing revealed resistance to isoniazid, rifampin, ethambutol, and rifabutin. Given that the patient took medication regularly, this observation suggests the possibility that some patients acquire drug resistance during SCC.

폐결핵의 초치료에서 표준 단기약물요법의 사용은 내성결핵의 발현을 줄일 수 있는 최선의 방법으로 받아들여지고 있다. 그러나 적절한 치료에도 불구하고 내성을 획득하여 다제내성결핵으로 진행한 이 증례는 표준 단기 약물요법이 일부 환자에게는 내성 획득을 완전히 예방할 수는 없을 수도 있다는 점을 시사한다.

Keywords

References

  1. World Health Organization. Treatment of tuberculosis guidelines. 4th ed. 2010.
  2. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662. https://doi.org/10.1164/rccm.167.4.603
  3. Zhang Y, Scorpio A, Nikaido H, Sun Z. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 1999;181:2044-2049.
  4. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986;133:423-430.
  5. Granich RM, Oh P, Lewis B, Porco TC, Flood J. Multidrug resistance among persons with tuberculosis in California, 1994-2003. JAMA 2005;293:2732-2739. https://doi.org/10.1001/jama.293.22.2732
  6. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002;295:2042-2046. https://doi.org/10.1126/science.1063814
  7. Mitchison DA. Basic mechanisms of chemotherapy. Chest 1979;76(6 Suppl):S771-S781. https://doi.org/10.1378/chest.76.6_Supplement.771
  8. Rastogi N, Goh KS, Horgen L, Barrow WW. Synergistic activities of antituberculous drugs with cerulenin and trans-cinnamic acid against Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 1998;21:149-157. https://doi.org/10.1111/j.1574-695X.1998.tb01161.x
  9. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003;7:6-21.
  10. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3(10 Suppl 2):S231-S279.